Critical evaluation of the efficacy and tolerability of azilsartan.
Appropriate control of blood pressure (BP) in hypertensive patients still represents the major therapeutic goal in the treatment of hypertension. Despite the growing attention and wide range of antihypertensive agents available in the clinical scenario, the target of BP below the advised thresholds of 140/90 mmHg is, unfortunately, often unreached. For this reason, the search for new antihypertensive agents is still ongoing. Azilsartan medoxomil, a new angiotensin receptor blocker that has been recently introduced in the clinical arena, represents the eighth angiotensin receptor blocker currently available for BP control. The aim of this paper is to describe the efficacy and safety profile of this new compound, reviewing available data obtained from both pre-clinical and clinical studies.
Istituto Scienze della Vita, Scuola Superiore Sant'Anna, Pisa, Italy. adecatro@yahoo.it
Alberto R
AR
De Caterina
Andrew R
AR
Harper
Florim
F
Cuculi
D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D004347:Drug Interactions; D019317:Evidence-Based Medicine; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D010069:Oxadiazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012084:Renin-Angiotensin System / Q000187:drug effects; D018570:Risk Assessment; D016896:Treatment Outcome
D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D010069:Oxadiazoles; C521273:azilsartan; C557413:azilsartan medoxomil